WallStSmart

Live Ventures Inc (LIVE)vsMEDIFAST INC (MED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Live Ventures Inc generates 37% more annual revenue ($434.25M vs $316.93M). LIVE leads profitability with a -0.6% profit margin vs -8.1%. MED earns a higher WallStSmart Score of 45/100 (D).

LIVE

Avoid

30

out of 100

Grade: F

Growth: 4.0Profit: 3.5Value: 6.7Quality: 5.0
Piotroski: 5/9Altman Z: 2.02

MED

Hold

45

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 6.0Quality: 8.5
Piotroski: 2/9Altman Z: 5.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LIVEUndervalued (+85.9%)

Margin of Safety

+85.9%

Fair Value

$138.16

Current Price

$8.08

$130.08 discount

UndervaluedFair: $138.16Overvalued

Intrinsic value data unavailable for MED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LIVE1 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

MED4 strengths · Avg: 9.3/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
5.0910/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.978/10

Growing faster than its price suggests

Areas to Watch

LIVE4 concerns · Avg: 2.8/10
Market CapQuality
$26.94M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.2%3/10

ROE of 4.2% — below average capital efficiency

Operating MarginProfitability
4.8%3/10

Operating margin of 4.8%

Revenue GrowthGrowth
-3.2%2/10

Revenue declined 3.2%

MED4 concerns · Avg: 2.5/10
Market CapQuality
$141.66M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-10.1%2/10

ROE of -10.1% — below average capital efficiency

Revenue GrowthGrowth
-27.6%2/10

Revenue declined 27.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : LIVE

The strongest argument for LIVE centers on Price/Book.

Bull Case : MED

The strongest argument for MED centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : LIVE

The primary concerns for LIVE are Market Cap, Return on Equity, Operating Margin. Debt-to-equity of 2.44 is elevated, increasing financial risk.

Bear Case : MED

The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

LIVE carries more volatility with a beta of 1.03 — expect wider price swings.

LIVE is growing revenue faster at -3.2% — sustainability is the question.

LIVE generates stronger free cash flow (5M), providing more financial flexibility.

Monitor HOME IMPROVEMENT RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MED scores higher overall (45/100 vs 30/100). LIVE offers better value entry with a 85.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Live Ventures Inc

CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA

Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.

Visit Website →

MEDIFAST INC

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Visit Website →

Want to dig deeper into these stocks?